Cover Image

Gallic Acid Impedes Non-Small Cell Lung Cancer Progression via Suppression of EGFR-Dependent CARM1-PELP1 Complex

Dong Wang,1 Burenbatu Bao2 1Department of Oncology of Mongolian-Western Medicine, Affiliated Hospital of Inner Mongolia University for Nationalities, Tongliao 028007, People’s Republic of China; 2Department of Mongolian Medicine Hematology & Oncology, Affiliated Hospital of Inner Mongo...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wang D (Author), Bao B (Author)
Format:	Book
Published:	Dove Medical Press, 2020-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Les Carmes Théâtre et patrimoine à Avignon
Published: (2019)

Long Non-coding RNA PVT1 Competitively Binds MicroRNA-424-5p to Regulate CARM1 in Radiosensitivity of Non-Small-Cell Lung Cancer
by: Dong Wang, et al.
Published: (2019)

The CARM1 transcriptome and arginine methylproteome mediate skeletal muscle integrative biology
by: Tiffany L. vanLieshout, et al.
Published: (2022)

Carme Albaigés, una artista singular
by: Ramon balius i juli
Published: (2006)

Retraction Notice to: Long Non-coding RNA PVT1 Competitively Binds MicroRNA-424-5p to Regulate CARM1 in Radiosensitivity of Non-Small-Cell Lung Cancer
by: Dong Wang, et al.
Published: (2022)

Gallic acid suppresses the progression of triple-negative breast cancer HCC1806 cells via modulating PI3K/AKT/EGFR and MAPK signaling pathways
by: Si Lin, et al.
Published: (2022)

Correlation of TTF-1 immunoexpression and EGFR mutation spectrum in non-small cell lung carcinoma
by: Tripti Nakra, et al.
Published: (2021)

Senescence Inducer Shikonin ROS-Dependently Suppressed Lung Cancer Progression
by: Hongming Zheng, et al.
Published: (2018)

EGR1, EGFR and IGF1R protein expressions in non-small cell lung cancer and their clinical significances
by: Dujuan Yu, et al.
Published: (2016)

Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR‐mutant non‐small cell lung cancer
by: Julie M. Janssen, et al.
Published: (2022)

Discovery and biological evaluation of novel CARM1/HDAC2 dual-targeting inhibitors with anti-prostate cancer agents
by: Sudong Liang, et al.
Published: (2023)

Gallic Acid Suppressed Tumorigenesis by an LncRNA MALAT1-Wnt/β-Catenin Axis in Hepatocellular Carcinoma
by: Chuan-jian Shi, et al.
Published: (2021)

ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer
by: Dantong Sun, et al.
Published: (2021)

EGFR mutation testing in non-small cell lung cancer (NSCLC)
by: Fouad Al Dayel
Published: (2012)

Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
by: Chen Shi, et al.
Published: (2023)

Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
by: Jianghua Ding, et al.
Published: (2024)

Hedgehog Suppresses Paclitaxel Sensitivity by Regulating Akt-Mediated Phosphorylation of Bax in EGFR Wild-Type Non-Small Cell Lung Cancer Cells
by: Yun-Chieh Tu, et al.
Published: (2022)

Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas
by: Gömöri Éva, et al.
Published: (2012)

Clinical and surgical implications of EGFR mutations in non-small cell lung cancer
by: M. Yoon, et al.
Published: (2016)

Non-small-cell lung cancer: how to manage EGFR-mutated disease
by: Federica Pecci, et al.
Published: (2022)

EGFR-gene analysis on cytological specimens of non-small-cell lung cancers
by: Feichter G, et al.
Published: (2007)

Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone
by: Yujia Wang, et al.
Published: (2021)

Stanisław Zięba, Bóg w życiu wielkich kompozytorów, Wydawnictwo Diecezji Pelp liński ej "Bemardinum", Pelpłin-Gdańsk 2001, ss. 196
by: Krzysztof Niegowski
Published: (2003)

Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer
by: Si-Yang Maggie Liu, et al.
Published: (2023)

Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
by: Jonathan R. Thompson, et al.
Published: (2016)

EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer
by: Fang S, et al.
Published: (2014)

ALK, ROS1 and EGFR status of lung cancers in the Aegean Region of Turkey
by: Gulden Diniz, et al.
Published: (2022)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
by: Po-Yen Chen, et al.
Published: (2021)

Complex relational needs impede progress in NHS Talking Therapies (IAPT): implications for public mental health
by: Orestis Zavlis, et al.
Published: (2023)

Targeting GLI1 and GLI2 with small molecule inhibitors to suppress GLI-dependent transcription and tumor growth
by: Luisa Maresca, et al.
Published: (2023)

MicroRNA-1298 is downregulated in non-small cell lung cancer and suppresses tumor progression in tumor cells
by: Zhonghai Du, et al.
Published: (2019)

Tyrosine kinase inhibitors: new molecules in non-small cell lung cancer (EGFR AND ALK)
by: Fernando Franco, et al.
Published: (2017)

Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer
by: Haoyue Hu, et al.
Published: (2023)

Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer
by: Yap TA, et al.
Published: (2014)

Prediction of EGFR Mutation Status in Non-Small Cell Lung Cancer Based on Ensemble Learning
by: Youdan Feng, et al.
Published: (2022)

Advancements in understanding cardiotoxicity of EGFR- TKIs in non-small cell lung cancer treatment and beyond
by: Xin Li, et al.
Published: (2024)

Inhalable Anti-EGFR Antibody-Conjugated Osimertinib Liposomes for Non-Small Cell Lung Cancer
by: Apoorva Daram, et al.
Published: (2024)

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
by: Connor O'Leary, et al.
Published: (2020)

Gallic acid mitigates diclofenac-induced liver toxicity by modulating oxidative stress and suppressing IL-1β gene expression in male rats
by: Mohsen Esmaeilzadeh, et al.
Published: (2020)

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
by: Yamin Shu, et al.
Published: (2022)